Orient Bio Strengthens Bio Infrastructure Business Based on AI and Precision Medicine

Expansion into Laboratory Animals, Non-Clinical Research, and AI Data Businesses

Jaejin Jang, Chairman of Orient Bio

On May 12, Orient Bio announced that it is strengthening its bio research infrastructure business in response to the expansion of the artificial intelligence (AI)-based drug development and precision medicine markets.

The company is expanding its business scope to become a platform company encompassing the entire bio research ecosystem, leveraging more than 35 years of accumulated expertise in laboratory animal production technology and non-clinical research support capabilities.

Recently, as the global bio industry rapidly transitions to AI-based predictive drug development systems, the importance of securing highly reproducible and reliable biological data has grown. In particular, standardized biological materials and highly reliable non-clinical data are considered essential factors for increasing the accuracy of AI-based drug development.

Orient Bio has established a supply system for a diverse range of biological materials required for non-clinical research, from rodents to beagles and primates. The company’s competitive edge lies in its ability to provide stable supply, based on its long-established production infrastructure and quality control system.

Industry experts believe that, in the era of AI-based drug development, building accurate and standardized data, rather than simply collecting data, will be the key competitive advantage. Accordingly, demand for high-quality biological materials and non-clinical research infrastructure is also expected to grow.

Orient Bio is now seeking to expand its business beyond the simple supply of biological materials to include disease model development, non-clinical research support, research infrastructure management, and the utilization of AI-based bio data.

In addition, as the global bio market grows and domestic bio companies increase their R&D investments, the demand for stable non-clinical research infrastructure is also expected to rise steadily.

A company official stated, “Non-clinical research is the starting point for global competitiveness in drug development,” adding, “We plan to contribute to the advancement of the domestic bio research ecosystem based on our accumulated research infrastructure.”

This content was produced with the assistance of AI translation services.